Browse FPR2

Summary
SymbolFPR2
Nameformyl peptide receptor 2
Aliases LXA4R; HM63; FMLPX; FPR2A; ALXR; FPRL1; formyl peptide receptor-like 1; FMLPXA; FMLP-R-I; FMLP-related recep ......
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein.
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Low affinity receptor for N-formyl-methionyl peptides, which are powerful neutrophils chemotactic factors. Binding of FMLP to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. The activation of LXA4R could result in an anti-inflammatory outcome counteracting the actions of proinflammatory signals such as LTB4 (leukotriene B4).

> Gene Ontology
 
Biological Process GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002430 complement receptor mediated signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0007200 phospholipase C-activating G-protein coupled receptor signaling pathway
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0050900 leukocyte migration
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0055074 calcium ion homeostasis
GO:0060326 cell chemotaxis
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
Molecular Function GO:0001653 peptide receptor activity
GO:0004875 complement receptor activity
GO:0004982 N-formyl peptide receptor activity
GO:0008528 G-protein coupled peptide receptor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04080 Neuroactive ligand-receptor interaction
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-444473: Formyl peptide receptors bind formyl peptides and many other ligands
R-HSA-418594: G alpha (i) signalling events
R-HSA-416476: G alpha (q) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolFPR2
Nameformyl peptide receptor 2
Aliases LXA4R; HM63; FMLPX; FPR2A; ALXR; FPRL1; formyl peptide receptor-like 1; FMLPXA; FMLP-R-I; FMLP-related recep ......
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FPR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FPR2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
17938258Hepatocellular CarcinomaPromote immunity (T cell function)In the present study, we showed that stimulation of FPRL1 agonist ligands (W peptide from a synthetic peptide library, N36 peptide from HIV-1 gp41, and F peptide from HIV-1 envelope protein gp120) elevated endogenous tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression in human THP-1 monocytes, primary neutrophils, and mouse leukocytes. Activation of nuclear factor kappaB was required by the FPRL1-mediated TRAIL expression in the human THP-1 cells and primary neutrophils. The increased TRAIL expression in the mice significantly suppressed the growth of transplanted mouse liver tumor cells by inducing apoptotic cell death.
Summary
SymbolFPR2
Nameformyl peptide receptor 2
Aliases LXA4R; HM63; FMLPX; FPR2A; ALXR; FPRL1; formyl peptide receptor-like 1; FMLPXA; FMLP-R-I; FMLP-related recep ......
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FPR2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFPR2
Nameformyl peptide receptor 2
Aliases LXA4R; HM63; FMLPX; FPR2A; ALXR; FPRL1; formyl peptide receptor-like 1; FMLPXA; FMLP-R-I; FMLP-related recep ......
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FPR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.430.236
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6370.294
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2850.594
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4230.51
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.6580.119
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.150.436
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0110.987
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0560.955
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2450.81
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3390.713
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0240.985
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1840.496
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FPR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.88.26.60.452
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.88.56.30.453
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFPR2
Nameformyl peptide receptor 2
Aliases LXA4R; HM63; FMLPX; FPR2A; ALXR; FPRL1; formyl peptide receptor-like 1; FMLPXA; FMLP-R-I; FMLP-related recep ......
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FPR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFPR2
Nameformyl peptide receptor 2
Aliases LXA4R; HM63; FMLPX; FPR2A; ALXR; FPRL1; formyl peptide receptor-like 1; FMLPXA; FMLP-R-I; FMLP-related recep ......
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FPR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FPR2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFPR2
Nameformyl peptide receptor 2
Aliases LXA4R; HM63; FMLPX; FPR2A; ALXR; FPRL1; formyl peptide receptor-like 1; FMLPXA; FMLP-R-I; FMLP-related recep ......
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FPR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFPR2
Nameformyl peptide receptor 2
Aliases LXA4R; HM63; FMLPX; FPR2A; ALXR; FPRL1; formyl peptide receptor-like 1; FMLPXA; FMLP-R-I; FMLP-related recep ......
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FPR2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFPR2
Nameformyl peptide receptor 2
Aliases LXA4R; HM63; FMLPX; FPR2A; ALXR; FPRL1; formyl peptide receptor-like 1; FMLPXA; FMLP-R-I; FMLP-related recep ......
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FPR2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFPR2
Nameformyl peptide receptor 2
Aliases LXA4R; HM63; FMLPX; FPR2A; ALXR; FPRL1; formyl peptide receptor-like 1; FMLPXA; FMLP-R-I; FMLP-related recep ......
Chromosomal Location19q13.3-q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FPR2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.